Sung R J, Keung E C, Nguyen N X, Huycke E C
Department of Medicine, San Francisco General Hospital, CA 94110.
J Clin Invest. 1988 Mar;81(3):688-99. doi: 10.1172/JCI113374.
To assess effects of beta-adrenergic blockade on ventricular tachycardia (VT) of various mechanisms, electrophysiology studies were performed before and after intravenous infusion of propranolol (0.2 mg/kg) in 33 patients with chronic recurrent VT, who had previously been tested with intravenous verapamil (0.15 mg/kg followed by 0.005 mg/kg/min infusion). In the verapamil-irresponsive group, 10 patients (group IA) had VT that could be initiated by programmed ventricular extrastimulation and terminated by overdrive ventricular pacing, and 11 patients (group IB) had VT that could be provoked by isoproterenol infusion (3-8 micrograms/min) but not by programmed electrical stimulation, and that could not be converted to a sustained sinus rhythm by overdrive ventricular pacing. Notably, in the group IA patients, all 10 patients had structural heart disease (coronary arteriosclerosis or idiopathic cardiomyopathy); beta-adrenergic blockade accelerated the VT rate in one patient but exerted no effects on the VT rate in the remaining 9 patients, and VT remained inducible in all 10 patients. By contrast, in the group IB patients, 7 of the 11 patients had no apparent structural heart disease; beta-adrenergic blockade completely suppressed the VT inducibility during isoproterenol infusion in all 11 patients. There were 12 patients with verapamil-responsive VT (group II). 11 of the 12 patients had no apparent structural heart disease. In these patients, the initiation of VT was related to attaining a critical range of cycle lengths during sinus, atrial-paced or ventricular-paced rhythm; beta-adrenergic blockade could only slow the VT rate without suppressing its inducibility. Of note, 14 of the total 33 patients had exercise provocable VT: two in group IA, five in group IB, and seven in group II. Thus, mechanisms of VT vary among patients, and so do their pharmacologic responses. Although reentry, catecholamine-sensitive automaticity, and triggered activity related to delayed afterdepolarizations are merely speculative, results of this study indicate that beta-adrenergic blockade is only specifically effective in a subset group (group IB) of patients with VT suggestive of catecholamine-sensitive automaticity.
为评估β-肾上腺素能阻滞剂对各种机制所致室性心动过速(VT)的影响,对33例慢性复发性VT患者在静脉输注普萘洛尔(0.2mg/kg)前后进行了电生理研究,这些患者此前已接受静脉维拉帕米(0.15mg/kg,随后以0.005mg/kg/min输注)测试。在维拉帕米无反应组中,10例患者(IA组)的VT可通过程序性心室额外刺激诱发,并通过超速心室起搏终止,11例患者(IB组)的VT可通过异丙肾上腺素输注(3 - 8μg/min)诱发,但不能通过程序性电刺激诱发,且不能通过超速心室起搏转为持续窦性心律。值得注意的是,IA组的所有10例患者均有结构性心脏病(冠状动脉粥样硬化或特发性心肌病);β-肾上腺素能阻滞剂使1例患者的VT速率加快,但对其余9例患者的VT速率无影响,且所有10例患者的VT仍可诱发。相比之下,IB组的11例患者中有7例无明显结构性心脏病;β-肾上腺素能阻滞剂完全抑制了所有11例患者在异丙肾上腺素输注期间的VT诱发性。有12例维拉帕米反应性VT患者(II组)。12例患者中有11例无明显结构性心脏病。在这些患者中,VT的诱发与窦性、心房起搏或心室起搏心律期间达到临界周期长度范围有关;β-肾上腺素能阻滞剂只能减慢VT速率,而不能抑制其诱发性。值得注意的是,33例患者中有14例运动可诱发VT:IA组2例,IB组5例,II组7例。因此,VT的机制在患者之间各不相同,其药理反应也是如此。虽然折返、儿茶酚胺敏感性自律性以及与延迟后去极化相关的触发活动只是推测,但本研究结果表明,β-肾上腺素能阻滞剂仅对提示儿茶酚胺敏感性自律性的VT患者亚组(IB组)具有特异性疗效。